Baseline plasma KL-6 level predicts adverse outcomes in patients with idiopathic pulmonary fibrosis receiving nintedanib: a retrospective real-world cohort study
Abstract Background Nintedanib is effective for treating idiopathic pulmonary fibrosis (IPF), but some patients may exhibit a suboptimal response and develop on-treatment acute exacerbation (AE-IPF), hepatic injury, or mortality. It remains unclear which patients are at risk for these adverse outcom...
Main Authors: | Tang-Hsiu Huang, Chin-Wei Kuo, Chian-Wei Chen, Yau-Lin Tseng, Chao-Liang Wu, Sheng-Hsiang Lin |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-05-01
|
Series: | BMC Pulmonary Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12890-021-01530-6 |
Similar Items
-
Serum Krebs von den Lungen (KL-6) level as a marker of exacerbation of interstitial lung diseases
by: Zainab H. Saeed, et al.
Published: (2020-11-01) -
Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis
by: Takumi Yoshikawa, et al.
Published: (2020-01-01) -
Serum SP-A and KL-6 levels can predict the improvement and deterioration of patients with interstitial pneumonia with autoimmune features
by: Jingxian Wang, et al.
Published: (2020-12-01) -
Serum concentrations of Krebs von den Lungen-6, surfactant protein D, and matrix metalloproteinase-2 as diagnostic biomarkers in patients with asbestosis and silicosis: a case–control study
by: Changjiang Xue, et al.
Published: (2017-11-01) -
Surfactant protein D: a useful marker for differentiation of drug-induced pneumonia and bacterial pneumonia
by: Yuko Waseda, et al.
Published: (2021-06-01)